03:39 PM EST - CML HealthCare Inc. : announced that its subsidiary, Hemostasis Reference Laboratory Inc. has been awarded a contract extension to work with Isis Pharmaceuticals on their Factor XI Phase II clinical trial. ISIS-FXIRX is an antisense drug designed to treat clotting disorders. HRL is currently the coagulation testing laboratory of choice for ISIS-FXIRX Phase I clinical trial. CML HealthCare Inc.
shares T.CLC are trading up $0.02 at $7.64.
